Findings show investigational drug reduces tics by 30%; Data presentation April 5
CHICAGO , March 31, 2022 /PRNewswire/ -- Emalex Biosciences, Inc. ("Emalex"), a biopharmaceutical company focused on developing treatments for central nervous system (CNS) movement disorders and fluency disorders, will present an abstract — "Ecopipam in Children and Adolescents with Tourette Syndrome: Results from a Randomized, Double-Blind, Placebo-Controlled Phase 2b Study"— at the American Academy of Neurology's (AAN) Annual Meeting, April 2-7 , in Seattle .
Findings show investigational drug reduces tics by 30% in pediatric patients with Tourette Syndrome.
Positive topline results from Emalex's Phase 2b clinical study (D1AMOND Study) evaluating the efficacy and safety of ecopipam (EBS-101), an investigational, first-in-class, dopamine-1 (D1) receptor antagonist, for the treatment of pediatric patients with Tourette Syndrome, were announced in late 2021. The results were statistically significant and clinically meaningful on the primary and multiple secondary efficacy endpoints. In the study the drug was also well tolerated by study participants.
"The robust results of our ecopipam study are very encouraging, giving us momentum to continue our important work towards a safe and effective therapy for pediatric patients living with Tourette Syndrome," said Atul R. Mahableshwarkar M.D ., Chief Medical Officer, Psychiatry, and Senior Vice President of Drug Development. "I am eager to publicly share full data of our study knowing we are one step closer to finding relief for people living with this disorder."
Abstract co-author Dr. Mahableshwarkar will present study findings on Tuesday, April 5 at 1:36 p.m. CT (11:36 a.m. PT ) in Ballroom 6E at the Washington State Convention Center.
About Ecopipam Ecopipam is an investigational first-in-class drug currently being evaluated for the treatment of Tourette Syndrome (TS) in pediatric patients and childhood-onset fluency disorder (stuttering) in adults. Ecopipam selectively blocks the actions of the neurotransmitter dopamine at the D1 receptor. Dopamine is a neurotransmitter in the central nervous system, and its receptors have been classified into two "families" based on their genetic structure: "D1" (including subtypes D1 and D5) and "D2" (including subtypes D2, D3, and D4). D1-receptor super-sensitivity may be a mechanism for the repetitive and compulsive behaviors associated with TS.
Ecopipam has been shown to be generally well tolerated in clinical trials conducted to date and has received Orphan Drug and Fast Track designation from the U.S. Food and Drug Administration for the treatment of patients with TS. Adverse events affecting primarily the central nervous system [CNS] (e.g., sedation, insomnia, psychiatric changes) and the gastrointestinal system (e.g., nausea and vomiting) are the most frequently reported side effects.
About Emalex Biosciences Emalex Biosciences is a biopharmaceutical company focused on developing treatments for central nervous system movement disorders and fluency disorders with limited or no treatment options. Aligned with its mission, the company is evaluating treatments for children and adolescents with Tourette syndrome and adults with childhood-onset fluency disorder, or stuttering. Headquartered in Chicago , Emalex is a portfolio company of Paragon Biosciences. For more information, visit: EmalexBiosciences.com.
About Paragon Biosciences Paragon is a life science innovator that creates, builds and funds innovative biology-based companies in cell and gene therapy, adaptive biology and advanced biotechnology. The company's current portfolio includes Castle Creek Biosciences, CiRC Biosciences, Emalex Biosciences, Evozyne, Harmony Biosciences, Qlarity Imaging, and a consistent flow of incubating companies created and supported by the Paragon Innovation Capital™ model. Paragon stands at the intersection of human need, life science, and company creation. For more information, please visit https://paragonbiosci.com/.
Media Contact: Evelyn M. O'Connor Paragon Biosciences 312-847-1335 eo@paragonbiosci.com
View original content:https://www.prnewswire.com/news-releases/emalex-biosciences-to-present-positive-results-for-pediatric-tourette-syndrome-study-at-aan-annual-meeting-301515141.html
Vertex is one step closer to getting its new pain pill approved, which could substitute for opioids that are highly addictive.
Yahoo Finance's Anjalee Khemlani details Dr. Anthony Fauci's addressing the latest COVID-19 strain, the Omicron BA.2 subvariant, changing health guidelines, and progress in the latest vaccines getting FDA approval.
Merck & Co Inc (NYSE: MRK) and Ridgeback Biotherapeutics will present data evaluating Lagevrio (molnupiravir), an oral COVID-19 antiviral, at the 2022 European Congress of Clinical Microbiology & Infectious Diseases. The presentation includes final analyses evaluating virologic outcomes throughout and following a five-day course of molnupiravir as part of the Phase 3 MOVe-OUT trial. At Day 3 of treatment, among patients with the infectious virus at baseline, infectious SARS-CoV-2 was detected in
The company dosed the first patient in a phase 1/2 study of its gene therapy candidate targeting a rare eye disease.
Betting on turnarounds in companies that others are too scared to touch can be a successful strategy for some investors. Farsighted investors who recognize the enduring potential of a business -- even during its most vulnerable hours -- can sometimes (but of course, not always) get outsize returns if they're right. One biotech stock that could be ripe for exactly that kind of play is Cassava Sciences (NASDAQ: SAVA), which is down over 70% from its high in July of last year as a result of a parade of misfortunes.
By David Bautz, PhD NASDAQ:TNXP READ THE FULL TNXP RESEARCH REPORT Business Update TNX-1500 to Enter Phase 1 Clinical Trial in 2H22 Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) recently highlighted new preclinical data for TNX-1500 showing long-term rejection free graft survival in heart and kidney allografts in non-human primates (NHPs). The studies were conducted at Massachusetts General
"Your genitals should smell like genitals, not 'Sunday Morning Sunshine.'"View Entire Post ›
Almost every day, Ark Invest buys at least a handful of innovation-heavy stocks for its collection of exchange-traded funds. Ark Invest founder and CEO Cathie Wood has a lot of confidence in the genomic revolution, and in two companies in particular. Hardly a day in March has gone by without Wood making purchases of Adaptive Biotechnologies (NASDAQ: ADPT), Burning Rock Biotech (NASDAQ: BNR), or both.
Vladimir Putin was visited by a thyroid cancer doctor 35 times at his luxury Black Sea retreat, and regularly takes steroids, according to documents revealing the autocrat’s state of health for the first time.
Welcome to Friday’s Overnight Health Care, where we’re following the latest moves on policy and news affecting your health. Subscribe here. It was a big day for U.S. soccer fans, as the U.S. men’s national team drew England and Iran in its group for the World Cup next fall. The House voted to decriminalize marijuana,…
Photo Illustration by Luis G. Rendon/The Daily Beast/Getty/Austin Fire Department/U.S. Department of Veterans AffairsA teenage neo-Nazi accused of torching a Texas synagogue last Halloween suffers from “a myriad of mental health issues,” but his parents—one of whom is a well-respected physician now serving as a high-ranking Veterans Affairs official—never got him the treatment he desperately needed, according to a federal magistrate judge.Further, the judge said, after doctors at a leading psych
The biotech firm was barely a decade old when the pandemic hit. "We essentially had to build the company overnight," HR chief Tracey Franklin tells Fortune.
There have been nearly 80 million total cases of COVID-19 in the US, and almost 975,000 deaths, according to stats from the "New York Times." Over the past two years, there have been times when it felt like everyone I knew was contracting the highly contagious virus, especially during the initial spike in cases, as well as during the surges caused by the delta and omicron variants.
China's most populous, wealthiest city was supposed to be shut down in 2 phases for about a week. That's been extended, and it could be extended again.
What exactly is the Omicron subvariant BA.2 and how concerned should you be? Experts weigh in.
Thomas Fisher figured he would end up in the very place he works, in the emergency room. Eventually, everyone passes through. Two springs ago, at the onset of the pandemic, he thought he might die of the thing he was treating in others. He updated his will, removed enough cash from the bank for six months, stocked his refrigerator. He doesn’t own a car so rather than risk contracting the virus ...
Shares of IPO stock Amylyx crumbled Thursday after a split FDA committee voted against its experimental ALS treatment.
U.S. lawmakers moved close to agreeing on a bipartisan compromise to provide a fresh $10 billion to combat COVID-19 on Thursday, a deal that could set up final congressional approval next week.
Identical twins Dr. Delana Wardlaw and Dr. Elana McDonald have been working tirelessly since the COVID-19 pandemic began to give back and keep their community healthy. For PEOPLE's Why I'm Getting Vaccinated Series, they share their personal experience
The legislation has little to no chance of passing the Senate or becoming law